# Phase I-II Multiple-Dose Safety and Efficacy Study of a Selective Inhibitor of Cyclooxygenase - 2 (SC-58635) in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients and Carriers

> **NCT00001693** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 20 (—)

## Conditions studied

- Colorectal Neoplasm
- Hereditary Nonpolyposis

## Interventions

- **DRUG:** Celecoxib (SC-58635)

## Key facts

- **NCT ID:** NCT00001693
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-03
- **Primary completion:** —
- **Final completion:** 2002-01
- **Target enrollment:** 20 (—)
- **Last updated:** 2008-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001693, "Phase I-II Multiple-Dose Safety and Efficacy Study of a Selective Inhibitor of Cyclooxygenase - 2 (SC-58635) in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients and Carriers". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT00001693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*